{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:56:32Z","timestamp":1768452992664,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["APP1092547"],"award-info":[{"award-number":["APP1092547"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>With direct-acting antivirals dramatically reshaping the public health response to the hepatitis C virus\u00a0(HCV), prisons are set to play a critical role in elimination efforts. Despite the theoretical demonstration of HCV treatment-as-prevention in prison in mathematical modeling, limited empirical data exist. The Australian \u2018Surveillance and Treatment of Prisoners with Hepatitis C\u2019 project (SToP-C) is the world\u2019s first trial of HCV treatment-as-prevention in prison. Drawing on interviews with HCV expert stakeholders, this paper explores the factors respondents identified as crucial to the success of future scale-up. Accounting for such perspectives matters because of the influence expert discourse has in shaping implementation.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Semi-structured interviews were conducted with nineteen HCV experts working across key policy, advocacy, research and clinical dimensions of the Australian HCV response. Data were coded using qualitative data management software (NVivo 11). Analysis proceeded via a hybrid deductive and inductive approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Notwithstanding concerns regarding the lack of primary prevention in Australian prisons, stakeholders reported broad levels of support for the intervention and for the future scale-up of HCV treatment. A number of considerations, both external and internal to the prison system, were identified as key. The principal external factor was an enabling political-cum-policy environment; internal factors included: obtaining support from prisons\u2019 executive and custodial staff; promoting health within a security-first institutional culture; allocating time for treatment within prisoners\u2019 tightly regulated schedules; ensuring institutional stability during treatment given the routine movement of prisoners between prisons; prioritizing the availability of retreatment given the paucity of primary prevention; and securing sufficient clinical space for treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The challenges to implementation are considerable, ranging from macrolevel concerns to in-prison logistical matters. Nonetheless, we argue that prisons remain an obvious setting for treatment scale-up, not only for prevention and potential elimination benefit, but for the treatment opportunities they afford a socially disadvantaged and underserved population. While noting widespread concerns among respondents regarding the paucity of primary prevention in Australian prisons, results indicate broad levels of support among expert stakeholders for HCV treatment scale-up in prison.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-021-00494-4","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T11:03:11Z","timestamp":1619434991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian \u2018surveillance and treatment of prisoners with hepatitis C\u2019 project (SToP-C)"],"prefix":"10.1186","volume":"18","author":[{"name":"the SToP-C Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7782-1235","authenticated-orcid":false,"given":"Jake","family":"Rance","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Lafferty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Treloar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"494_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.20517\/2394-5079.2018.53","volume":"4","author":"T Papaluca","year":"2018","unstructured":"Papaluca T, Thompson A. HCV elimination: breaking down the barriers to prison based care. Hepatoma Res. 2018;4:64.","journal-title":"Hepatoma Res"},{"key":"494_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.drugpo.2017.08.001","volume":"47","author":"J Grebely","year":"2017","unstructured":"Grebely J, Bruneau J, Bruggmann P, Harris M, Hickman M, Rhodes T, et al. Elimination of hepatitis C virus infection among PWID: the beginning of a new era of interferon-free DAA therapy. Int J Drug Policy. 2017;47:26\u201333.","journal-title":"Int J Drug Policy"},{"issue":"10049","key":"494_CR3","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S0140-6736(16)30466-4","volume":"388","author":"K Dolan","year":"2016","unstructured":"Dolan K, Wirtz AL, Moazen B, Ndeffo-mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. The Lancet. 2016;388(10049):1089\u2013102.","journal-title":"The Lancet"},{"key":"494_CR4","unstructured":"Butler T, Simpson M. National Prison Entrants\u2019 Blood-borne Virus Survey Report 2004, 2007, 2010, 2013, and 2016. Kirby Institute (UNSW Sydney); 2017."},{"issue":"1","key":"494_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1108\/IJPH-09-2014-0032","volume":"11","author":"NM Wright","year":"2015","unstructured":"Wright NM, Tompkins CN, Farragher TM. Injecting drug use in prison: prevalence and implications for needle exchange policy. Int J Prison Health. 2015;11(1):17\u201329.","journal-title":"Int J Prison Health"},{"issue":"9","key":"494_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/jvh.12701","volume":"24","author":"EB Cunningham","year":"2017","unstructured":"Cunningham EB, Hajarizadeh B, Bretana NA, Amin J, Betz-Stablein B, Dore GJ, et al. Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005\u20132014: the HITS-p study. J Viral Hepatitis. 2017;24(9):733\u201341.","journal-title":"J Viral Hepatitis"},{"key":"494_CR7","doi-asserted-by":"crossref","unstructured":"Wallace J, Richmond J, Ellard J, Power J, Lucke J. Eradicating hepatitis C: the need for a public health response. Global Public Health. 2017:1\u201311.","DOI":"10.1080\/17441692.2017.1342851"},{"issue":"3","key":"494_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0038-1666841","volume":"38","author":"JV Lazarus","year":"2018","unstructured":"Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis. 2018;38(3):181\u201392.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"494_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.idc.2018.02.006","volume":"32","author":"GJ Dore","year":"2018","unstructured":"Dore GJ, Hajarizadeh B. Elimination of hepatitis C virus in Australia: laying the foundation. Infect Dis Clin N Am. 2018;32(2):269\u201379.","journal-title":"Infect Dis Clin N Am"},{"issue":"4","key":"494_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S2468-1253(16)30075-9","volume":"1","author":"B Hajarizadeh","year":"2016","unstructured":"Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ. Hepatitis C treatment as prevention: evidence, feasibility, and challenges. Lancet Gastroenterol Hepatol. 2016;1(4):317\u201327.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"494_CR11","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis","author":"World Health Organisation","year":"2016","unstructured":"World Health Organisation. Global health sector strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis. Geneva: World Health Organisation; 2016."},{"issue":"1","key":"494_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/epirev\/mxx019","volume":"40","author":"JV Lazarus","year":"2018","unstructured":"Lazarus JV, Safreed-Harmon K, Hetherington KL, Bromberg DJ, Ocampo D, Graf N, et al. Health outcomes for clients of needle and syringe programs in prisons. Epidemiol Rev. 2018;40(1):96\u2013104.","journal-title":"Epidemiol Rev"},{"issue":"3","key":"494_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/add.14012","volume":"113","author":"L Platt","year":"2018","unstructured":"Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a cochrane review and meta-analysis. Addiction. 2018;113(3):545\u201363.","journal-title":"Addiction"},{"key":"494_CR14","doi-asserted-by":"crossref","unstructured":"Blogg J, Wright T, McGrath C, Clegg J. Hepatitis C reinfection in prisons with broad access to direct acting antiviral treatments. Int J Drug Policy. 2020:102597.","DOI":"10.1016\/j.drugpo.2019.11.005"},{"key":"494_CR15","doi-asserted-by":"crossref","unstructured":"Luciani F, Breta\u00f1a N, Teutsch S, Amin J, Topp L, Dore G. A prospective study of hepatitis C incidence in Australian prisoners. Addiction. 2014;109.","DOI":"10.1111\/add.12643"},{"issue":"4","key":"494_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","volume":"67","author":"JV Lazarus","year":"2017","unstructured":"Lazarus JV, Wiktor S, Colombo M, Thursz M. Micro-elimination\u2014a path to global elimination of hepatitis C. J Hepatol. 2017;67(4):665\u20136.","journal-title":"J Hepatol"},{"issue":"3","key":"494_CR17","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/cid\/ciy210","volume":"67","author":"SR Bartlett","year":"2018","unstructured":"Bartlett SR, Fox P, Cabatingan H, Jaros A, Gorton C, Lewis R, et al. Demonstration of near-elimination of hepatitis C virus among a prison population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project. Clin Infect Dis. 2018;67(3):460\u20133.","journal-title":"Clin Infect Dis"},{"key":"494_CR18","unstructured":"Breta\u00f1a NA, Gray RR, Cunningham EB, Betz-Stablein B, Ribeiro R, Graw F, et al. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study. Addiction."},{"issue":"1","key":"494_CR19","doi-asserted-by":"publisher","first-page":"16849","DOI":"10.1038\/s41598-019-52564-0","volume":"9","author":"OO Dalgic","year":"2019","unstructured":"Dalgic OO, Samur S, Spaulding AC, Llerena S, Cobo C, Ayer T, et al. Improved health outcomes from hepatitis C treatment scale-up in Spain\u2019s prisons: a cost-effectiveness study. Sci Rep. 2019;9(1):16849.","journal-title":"Sci Rep"},{"key":"494_CR20","unstructured":"The Kirby Institute. Surveillance and Treatment of Prisoners With Hepatitis C (SToP-C) ClinicalTrials.gov: U.S. National Library of Medicine; 2019 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02064049?term=Prison&cond=Hepatitis+C&cntry=AU&draw=2&rank=2."},{"key":"494_CR21","doi-asserted-by":"crossref","unstructured":"Rance J, Lafferty L, Treloar C. \u2018Behind closed doors, no one sees, no one knows\u2019: hepatitis C, stigma and treatment-as-prevention in prison. Crit Public Health. 2018:1\u201311.","DOI":"10.1080\/09581596.2018.1541225"},{"issue":"12","key":"494_CR22","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/jvh.12987","volume":"25","author":"L Lafferty","year":"2018","unstructured":"Lafferty L, Rance J, Grebely J, Lloyd AR, Dore GJ, Treloar C. Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison. J Viral Hepat. 2018;25(12):1526\u201332.","journal-title":"J Viral Hepat"},{"key":"494_CR23","doi-asserted-by":"publisher","first-page":"102693","DOI":"10.1016\/j.drugpo.2020.102693","volume":"77","author":"L Lafferty","year":"2020","unstructured":"Lafferty L, Rance J, Grebely J, Dore GJ, Lloyd AR, Treloar C. Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting. Int J Drug Policy. 2020;77:102693.","journal-title":"Int J Drug Policy"},{"key":"494_CR24","unstructured":"Lafferty L, Rance J, Dore GJ, Lloyd AR, Treloar C. The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting. Addiction."},{"key":"494_CR25","unstructured":"Rance J, Lafferty L, Treloar C. Expert stakeholder perspectives on the acceptability of treatment-as-prevention in prison: A qualitative sub-study of the \u2018Surveillance and Treatment of Prisoners with Hepatitis C\u2019 project (SToP-C) Addiction. (Accepted)."},{"issue":"1","key":"494_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14780887.2013.801543","volume":"11","author":"OC Robinson","year":"2014","unstructured":"Robinson OC. Sampling in interview-based qualitative research: a theoretical and practical guide. Qual Res Psychol. 2014;11(1):25\u201341.","journal-title":"Qual Res Psychol"},{"key":"494_CR27","volume-title":"Fifth national hepatitis C strategy 2018\u20132022","author":"Australian Government Department of Health and Ageing","year":"2019","unstructured":"Australian Government Department of Health and Ageing. Fifth national hepatitis C strategy 2018\u20132022. Canberra: Commonwealth of Australia; 2019."},{"key":"494_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/160940690600500107","volume":"5","author":"J Fereday","year":"2006","unstructured":"Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: a hybrid approach of inductive and deductive coding and theme development. Int J Qual Methods. 2006;5:1\u201311.","journal-title":"Int J Qual Methods"},{"key":"494_CR29","volume-title":"Increasing the scale of population health interventions: a guide","author":"A Milat","year":"2014","unstructured":"Milat A, Newson R, King L. Increasing the scale of population health interventions: a guide. Sydney: NSW Ministry of Health; 2014."},{"issue":"1","key":"494_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","volume":"17","author":"M Sekhon","year":"2017","unstructured":"Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17(1):88.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"494_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/13645579.2015.1123555","volume":"20","author":"K Lancaster","year":"2017","unstructured":"Lancaster K. Confidentiality, anonymity and power relations in elite interviewing: conducting qualitative policy research in a politicised domain. Int J Soc Res Methodol. 2017;20(1):93\u2013103.","journal-title":"Int J Soc Res Methodol"},{"key":"494_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.socscimed.2012.11.021","volume":"78","author":"C May","year":"2013","unstructured":"May C. Agency and implementation: Understanding the embedding of healthcare innovations in practice. Soc Sci Med. 2013;78:26\u201333.","journal-title":"Soc Sci Med"},{"issue":"8","key":"494_CR33","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2105\/AJPH.93.8.1261","volume":"93","author":"RE Glasgow","year":"2003","unstructured":"Glasgow RE, Lichtenstein E, Marcus AC. Why don\u2019t we see more translation of health promotion research to practice? Rethinking the efficacy-to-effectiveness transition. Am J Public Health. 2003;93(8):1261\u20137.","journal-title":"Am J Public Health"},{"key":"494_CR34","doi-asserted-by":"publisher","first-page":"f6753","DOI":"10.1136\/bmj.f7086","volume":"347","author":"DH Peters","year":"2013","unstructured":"Peters DH, Adam T, Alonge O, Agyepong IA, Tran N. Implementation research: what it is and how to do it. BMJ. 2013;347:f6753.","journal-title":"BMJ"},{"issue":"3","key":"494_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/add.12051","volume":"108","author":"J Neale","year":"2013","unstructured":"Neale J, Hunt G, Lankenau S, Mayock P, Miller P, Sheridan J, et al. Addiction journal is committed to publishing qualitative research. Addiction. 2013;108(3):447\u20139.","journal-title":"Addiction"},{"key":"494_CR36","doi-asserted-by":"crossref","unstructured":"Bonnycastle KD. Injecting risk into prison sentences: a quantitative analysis of a prisoner-driven survey to measure HCV\/HIV seroprevalence, risk practices and viral testing at one Canadian male federal prison. Prison J. 2011;91.","DOI":"10.1177\/0032885511409893"},{"issue":"1","key":"494_CR37","doi-asserted-by":"publisher","first-page":"1670449","DOI":"10.1080\/16549716.2019.1670449","volume":"12","author":"HTV Zomahoun","year":"2019","unstructured":"Zomahoun HTV, Ben Charif A, Freitas A, Garvelink MM, Menear M, Dugas M, et al. The pitfalls of scaling up evidence-based interventions in health. Glob Health Action. 2019;12(1):1670449.","journal-title":"Glob Health Action"},{"issue":"12","key":"494_CR38","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1111\/add.14777","volume":"114","author":"L Maher","year":"2019","unstructured":"Maher L, Neale J. Adding quality to quantity in randomized controlled trials of addiction prevention and treatment: a new framework to facilitate the integration of qualitative research. Addiction. 2019;114(12):2257\u201366.","journal-title":"Addiction"},{"issue":"3","key":"494_CR39","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2105\/AJPH.2011.300374","volume":"102","author":"J Pont","year":"2012","unstructured":"Pont J, St\u00f6ver H, Wolff H. Dual loyalty in prison health care. Am J Public Health. 2012;102(3):475\u201380.","journal-title":"Am J Public Health"},{"issue":"2","key":"494_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1108\/IJPH-03-2016-0007","volume":"12","author":"SA Allen","year":"2016","unstructured":"Allen SA, Aburabi R. When security and medicine missions conflict: confidentiality in prison settings. Int J Prison Health. 2016;12(2):73\u20137.","journal-title":"Int J Prison Health"},{"issue":"1","key":"494_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12954-018-0246-6","volume":"15","author":"L Lafferty","year":"2018","unstructured":"Lafferty L, Wild TC, Rance J, Treloar C. A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia\u2019s prisons. Harm Reduct J. 2018;15(1):39.","journal-title":"Harm Reduct J"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00494-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-021-00494-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00494-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T11:15:02Z","timestamp":1619435702000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00494-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["494"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00494-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"24 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the following Human Research Ethics Committees: Justice Health & Forensic Mental Health Network (G621\/13); Corrective Services NSW (qualitative sub-study approval on April 5, 2016); and Aboriginal Health and Medical Research Council of NSW (1253\/17) and UNSW Sydney (HC15645).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JR and LL have nothing to declare. CT has received speaker fees from AbbVie and Gilead Sciences and research funding from Merck.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}